Related Experiment Video

Updated: Sep 10, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

[Inhibition of angiogenesis with antisense ODN of VEGF]

F Dong1, Y Jin

  • 1State Key Lab of Molecular Biology, Shanghai Institute of Biochemistry, Academia Sinica.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|July 1, 1997
PubMed
Abstract

Insights

Antisense oligodeoxynucleotides (ODNs) targeting VEGF show promise for cancer treatment. Specific modifications and sequences effectively inhibit tumor angiogenesis and growth, suggesting potential as new antitumor drugs.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Context:

  • Cancer angiogenesis is crucial for tumor growth and metastasis.
  • Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis.
  • Antisense oligodeoxynucleotides (ODNs) offer a targeted approach to inhibit gene expression.

Purpose:

  • To evaluate the efficacy of VEGF antisense ODNs in inhibiting angiogenesis and tumor growth.
  • To determine the optimal modifications and sequences of ODNs for antitumor activity.

Summary:

  • Five different VEGF antisense ODNs were tested in a mouse corneal tumor model.
  • ODNs with partial phosphorothioate modification or hairpin structures demonstrated significant inhibition of tumor-induced angiogenesis.
  • Linear ODNs were ineffective, while a combination of two specific ODNs yielded the best results in suppressing tumor growth.

Impact:

  • VEGF antisense ODNs show potential as novel therapeutic agents for cancer treatment.
  • This study highlights the importance of ODN design, including modifications and sequence, for effective antiangiogenic and antitumor activity.
  • The findings support the development of targeted therapies to combat angiogenesis in cancer.

More Related Videos

In Vitro Model of Coronary Angiogenesis08:03

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...